• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neurological manifestations of COVID-19: a retrospective observational study based on 1060 patients with a narrative review
CONCLUSION: Our data are coherent with the published literature. Knowledge of these patterns will make clinicians consider COVID-19 infection when unexplained neurological findings are encountered.PMID:36451533 | DOI:10.1177/02841851221138557
Source: Acta Radiologica - December 1, 2022 Category: Radiology Authors: Alberto Negro Mario Tortora Laura Gemini Arturo de Falco Francesco Somma Vincenzo d'Agostino Source Type: research

Neurological consequences of COVID-19
Pharmacol Rep. 2022 Sep 30. doi: 10.1007/s43440-022-00424-6. Online ahead of print.ABSTRACTIn December 2019, cases of pneumonia caused by infection with the previously unknown severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to coronavirus disease 2019 (COVID-19), were identified. Typical manifestations of COVID-19 are fever, cough, fatigue and dyspnoea. Initially, it was thought that the mechanism of action of SARS-CoV-2 was only associated with respiratory tract invasion, but it was later revealed that the infection might involve many other organs and systems, including the central and peripheral ner...
Source: Pharmacological Reports - September 30, 2022 Category: Drugs & Pharmacology Authors: Waldemar Brola Maciej Wilski Source Type: research

A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes.
Abstract Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in humans and their incidence is on the rise globally. Given their substantial contribution towards the escalating costs of health care, they also generate a high socio-economic burden in the general population. The underlying pathogenesis and progression associated with nearly all CVDs is predominantly of atherosclerotic origin that leads to the development of coronary artery disease, cerebrovascular disease, venous thromboembolism and, peripheral vascular disease, subsequently causing myocardial infarction, cardiac ar...
Source: Current Pharmaceutical Design - September 24, 2019 Category: Drugs & Pharmacology Authors: Flora GD, Nayak MK Tags: Curr Pharm Des Source Type: research

MassDevice.com +5 | The top 5 medtech stories for March 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. GlucoMe tackles connected diabetes management with acoustic data transmission The Centers for Disease Control & Prevention predict that by 2050, if current trends continue, 1 in 3 adults in the U.S. will have diabetes. The d...
Source: Mass Device - March 17, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: News Well Plus 5 Source Type: news

Relationship between body mass index and left atrial appendage thrombus in nonvalvular atrial fibrillation
Abstract Atrial fibrillation and obesity are two major growing epidemics in the United States and globally. Obese people are at the increased risk of developing atrial fibrillation. The contribution of obesity as an independent risk factor for stroke in the setting of atrial fibrillation remains unclear. We tested the hypothesis that non-valvular atrial fibrillation (NVAF) patients with increased body mass index (BMI) would be at increased risk for the development of left atrial appendage thrombus (LAAT). Consecutive, anticoagulation naïve patients with NVAF referred for a transesophageal echocardiogram (TEE) bet...
Source: Journal of Thrombosis and Thrombolysis - August 18, 2015 Category: Hematology Source Type: research

Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future
Atrial fibrillation (AF) is now said to be at epidemic proportions.1 Although symptoms and heart failure are two of the main reasons that patients with AF suffer from reduced quality of life, thromboembolic complications, particularly stroke, remain the major determinant of significant morbidity and mortality.2 Importantly, the risk of thromboembolism (TE) is completely irrespective of symptoms, and hence the sad fact that people continue to present with catastrophic stroke in AF with no prior history of its detection.3 Appropriate anticoagulation is imperative to reduce the TE/stroke risk. Numerous large scale studies hav...
Source: Heart - February 18, 2013 Category: Cardiology Authors: Rajappan, K. Tags: Drugs: cardiovascular system, Epidemiology Editorials Source Type: research